C4 Therapeutics, Inc. (CCCC) stock
CCCCNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/3019% above fair value
$2.77−0.12 (-4.15%)
Close on Nov 12, 2026Market cap $340.78MP/E –Yield –
C4 Therapeutics profit margin
Profit margin (net margin) is net income as a percentage of revenue.
C4 Therapeutics's profit margin for the twelve months ending Sep 30, 2026 was -282.2%. For fiscal 2025 it was -292.1%, against -296.0% the year before. The highest annual figure on record is -183.2% in fiscal 2021.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -292.1% | +3.9 |
| FY2024 | Dec 31, 2024 | -296.0% | +342.4 |
| FY2023 | Dec 31, 2023 | -638.3% | −226.1 |
| FY2022 | Dec 31, 2022 | -412.2% | −229.0 |
| FY2021 | Dec 31, 2021 | -183.2% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -257.9% | +28.5 |
| Q2 FY2026 | Jun 30, 2026 | -355.9% | +46.7 |
| Q1 FY2026 | Mar 31, 2026 | -408.5% | −44.8 |
| Q4 FY2025 | Dec 31, 2025 | -186.0% | +481.9 |
| Q3 FY2025 | Sep 30, 2025 | -286.4% | −125.9 |
| Q2 FY2025 | Jun 30, 2025 | -402.6% | −255.0 |
| Q1 FY2025 | Mar 31, 2025 | -363.7% | +569.6 |
| Q4 FY2024 | Dec 31, 2024 | -667.8% | +397.9 |
| Q3 FY2024 | Sep 30, 2024 | -160.6% | +83.6 |
| Q2 FY2024 | Jun 30, 2024 | -147.6% | +1200.9 |
| Q1 FY2024 | Mar 31, 2024 | -933.2% | −8.0 |
| Q4 FY2023 | Dec 31, 2023 | -1065.7% | +237.2 |
| Q3 FY2023 | Sep 30, 2023 | -244.2% | +229.0 |
| Q2 FY2023 | Jun 30, 2023 | -1348.4% | −1150.3 |
| Q1 FY2023 | Mar 31, 2023 | -925.2% | −512.1 |
| Q4 FY2022 | Dec 31, 2022 | -1302.9% | −1224.9 |
| Q3 FY2022 | Sep 30, 2022 | -473.2% | −182.8 |
| Q2 FY2022 | Jun 30, 2022 | -198.1% | +32.7 |
| Q1 FY2022 | Mar 31, 2022 | -413.1% | – |
| Q4 FY2021 | Dec 31, 2021 | -78.0% | – |
| Q3 FY2021 | Sep 30, 2021 | -290.4% | – |
| Q2 FY2021 | Jun 30, 2021 | -230.9% | – |
See a number that looks wrong?